Safety Watch: Compounded Tirzepatide Adverse Events, a New Impurity, and Counterfeits
Released: Last reviewed:
Adverse-event reports, a newly identified impurity, and counterfeits have raised the safety stakes for compounded tirzepatide. Here is what was found and how to protect yourself.
By Dr. Parmis, Lead Medical Researcher · Medically reviewed by Adam Kennah, M.D. · Last reviewed July 9, 2026 · Sources cited at the end.
Direct answer
Safety signals around compounded GLP-1s have grown. The FDA has logged 455+ adverse-event reports for compounded semaglutide and 320+ for compounded tirzepatide (as of early 2025), many tied to dosing errors from multi-dose vials. In March 2026, researchers identified a tirzepatide-B12 adduct in some mass-compounded tirzepatide-with-B12 products — an impurity absent from FDA-approved tirzepatide, with unknown safety. Counterfeit and falsely labeled products have also appeared online. None of these apply to FDA-approved Mounjaro or Zepbound.
Where the risk concentrates
Two patterns dominate the reports: dosing errors, where patients draw the wrong amount from a multi-dose vial, and product-quality issues from unverified sourcing. Both are more likely with mass-compounded vials and gray-market vendors than with prefilled, FDA-approved pens.
Adverse-event reports (as of early 2025)
Safety signals summarized
| Signal | What was found | Applies to |
|---|---|---|
| Adverse events | 455+ semaglutide, 320+ tirzepatide reports | Compounded products |
| Dosing errors | Wrong doses drawn from multi-dose vials; some hospitalizations | Compounded vials |
| B12 adduct (Mar 2026) | Novel tirzepatide-B12 compound, unknown safety | Mass-compounded tirzepatide+B12 |
| Counterfeits | Falsely labeled product, non-existent pharmacies named | Online/gray-market supply |
How to protect yourself
Where possible, choose FDA-approved products. If you use compounded medicine under a documented clinical need, verify the pharmacy pathway, request a certificate of analysis, confirm concentration and fill volume, and never self-adjust a vial dose without clinician guidance. Our quality and sterility guide and safety overview go deeper. This is a sensitive area; if a product seems off, stop and consult a licensed clinician.
How dosing errors happen with vials
Most FDA-approved tirzepatide comes in prefilled, fixed-dose pens. Much compounded tirzepatide arrives as a multi-dose vial with syringes, requiring the patient to draw the correct number of units each week. That extra step is where many reported errors occur: a patient measures in the wrong units, uses the wrong concentration, or misreads a titration change and injects several times the intended dose. Some of these errors led to hospitalization. Prefilled, single-dose delivery is specifically designed to eliminate this failure mode.
What FDA-approved products avoid
Approved Mounjaro and Zepbound are manufactured under strict quality controls, carry verified concentration and labeling, and are distributed through channels that make counterfeiting far harder. They are not implicated in the impurity and counterfeit findings above, which involve compounded or gray-market supply. That difference — verified identity, strength, and sourcing — is the core practical safety argument for approved products where a patient can access them. This is a sensitive topic; if you have any doubt about a product you have received, do not use it and contact a licensed clinician or pharmacist.
Frequently asked questions
How many adverse events have been reported? As of early 2025 the FDA had logged 455+ reports tied to compounded semaglutide and 320+ tied to compounded tirzepatide, many involving dosing errors from multi-dose vials.
What is the tirzepatide-B12 impurity? A March 2026 analysis identified a tirzepatide-B12 adduct in some mass-compounded tirzepatide-with-B12 products — a compound not present in FDA-approved tirzepatide, with unknown safety.
Are counterfeits a real risk? Yes. The FDA has documented counterfeit and falsely labeled tirzepatide entering the market through online channels, sometimes naming pharmacies that do not exist.
How do I lower my risk? Prefer FDA-approved products where possible; if using compounded medicine, verify the pharmacy pathway, request certificates of analysis, and never self-adjust doses from a vial without guidance.
July 9, 2026: Published; safety signals compiled from FDA materials and 2026 reporting.
March 2026: Tirzepatide-B12 adduct identified in some mass-compounded products.
Sources
- FDA — press materials on compounded GLP-1 adverse events and enforcement
- Pharmacy Times — adverse-event and safety reporting on compounded GLP-1s
- Portrait Care — March 2026 tirzepatide-B12 adduct finding (secondary summary)
Important: Compounded tirzepatide is not FDA-approved and is not the same medicine as Mounjaro or Zepbound, the only FDA-approved tirzepatide products (Eli Lilly and Company). This page is educational and is not medical or legal advice. Weight-loss medications require evaluation and, when appropriate, a prescription from a licensed clinician. Individual results and side effects vary. Confirm current FDA status, pricing, and clinical guidance directly before acting.